Streetbeat News

Equity Actions

VEEV

Analysts have published 18 ratings on Veeva Systems (NYSE:VEEV) in the last three months, with a diverse range of views. The average 12-month price target is $209.44, down 3.56% from the previous average. Analysts have made various adjustments to their ratings and price targets, with some raising and others lowering their expectations. Veeva is a leading provider of cloud-based software for the life sciences industry. Financial indicators show strong market presence, profitability, and financial management, with a market cap above industry average, positive revenue trend, high net margin, ROE, and ROA, and low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 8:01 pm

SLAB

Analysts have provided mixed reviews on Silicon Laboratories (NASDAQ:SLAB) over the past three months, with 6 ratings ranging from bullish to indifferent. The average 12-month price target is now $132.67, down from $153.20, with a high estimate of $170.00 and a low of $86.00. Analysts from firms like Stifel, JP Morgan, Morgan Stanley, and Keybanc have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Silicon Laboratories develops solutions for various markets and has a market cap below the industry average. It experienced a revenue decline of -24.48% as of September 30, 2023, but has strong net margin, ROE, and ROA figures, and a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 8:01 pm

PDD

PDD Holdings (NASDAQ:PDD) received 4 bullish analyst ratings in the latest quarter, with a 12-month average price target of $174.25, up from $145.50. Analysts from Benchmark and Goldman Sachs raised their price targets, reflecting positive sentiment based on the company's strong financial performance, including a 93.89% revenue growth rate, a 22.57% net margin, and an ROE of 10.11%. PDD Holdings operates a portfolio of businesses and aims to integrate more businesses into the digital economy.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 8:01 pm

VAC

Marriott Vacations (NYSE:VAC) received mixed analyst ratings in the latest quarter, with 5 analysts offering a range of views. The average 12-month price target is $104.6, with a high of $149.00 and a low of $65.00, reflecting a 24.2% decrease in the average target. Analysts from Jefferies, B of A Securities, Truist Securities, and JP Morgan have adjusted their ratings and price targets, indicating a shift in sentiment. Marriott Vacations operates in the leisure industry, primarily in the US, with challenges in revenue growth, net margin, ROE, ROA, and a conservative debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 8:01 pm

EXAS

Exact Sciences (NASDAQ:EXAS) has been rated by 5 analysts in the past three months, with 3 bullish and 2 somewhat bullish ratings. The average 12-month price target is $88.2, with a high of $91.00 and a low of $80.00, marking a 7.16% decrease in the average target. Analysts from Benchmark, Guggenheim, Goldman Sachs, and Piper Sandler have provided recent evaluations, with some lowering their price targets. Exact Sciences, known for its cancer screening tests, shows a positive revenue trend but lags in growth rate compared to peers, has a strong net margin, but faces challenges in ROE and excels in ROA. The company maintains a prudent debt management with a debt-to-equity ratio of 0.82.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 8:00 pm

ARWR

Arrowhead Pharma (NASDAQ:ARWR) has been analyzed by 4 analysts, showing a mix of bullish and indifferent sentiments. The average 12-month price target is $38.25, up from the previous $34.50. Analysts from B of A Securities and Morgan Stanley have adjusted their price targets, while RBC Capital maintains a high estimate. Arrowhead's financials indicate a market cap above industry average, a significant revenue decline, high net margin, and low ROE and ROA. The company has a conservative debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 8:00 pm

BBWI

Goldman Sachs has maintained its Buy rating on Bath & Body Works but has removed the company from its Conviction List. This adjustment suggests that while Goldman Sachs still sees positive prospects for Bath & Body Works, it may no longer view the stock as a top pick with the highest conviction.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 7:45 pm

NYT

Farallon Capital Partners, L.P. has disclosed a 5.8% passive stake in The New York Times Company, indicating a significant investment by the firm in the media company.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 7:35 pm

RSG

Republic Servs Inc. (NYSE:RSG) stock is currently at $164.80, with a recent decrease of 0.07%. Over the past month, RSG's stock increased by 2.07%, and over the past year, by 28.50%. The article discusses the company's P/E ratio in comparison to the industry average, suggesting that RSG's lower P/E might indicate it is undervalued or expected to perform worse than its peers. The importance of using the P/E ratio in conjunction with other financial metrics for investment decisions is emphasized.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 7:30 pm

UNP

Union Pacific Inc. (NYSE:UNP) stock dropped 0.67% to $243.98 in the current session, but increased by 5.19% over the past month and 16.71% over the past year. The P/E ratio of Union Pacific is 23.57, lower than the Ground Transportation industry average of 29.58, suggesting it might be undervalued or expected to perform worse than its peers.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 7:15 pm